



UnitedHealthcare Pharmacy  
Clinical Pharmacy Programs

Program Number	2019 P 3111-3
Program	Step Therapy - COPD
Medication	Seebri Neohaler (glycopyrrolate)
P&T Approval Date	6/2018, 5/2019, 6/2019
Effective Date	9/1/2019; Oxford only: 9/1/2019

**1. Background:**

Seebri Neohaler (glycopyrrolate) is indicated for the long-term, maintenance treatment of airflow obstruction or bronchospasm in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Step therapy programs are intended to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try an alternative long-acting antimuscarinic agent before providing coverage for Seebri Neohaler. Members, who have received at least a 90 day supply of Seebri Neohaler in the past 120 days as documented in claims history, will be allowed continued coverage of their current therapy.

**2. Coverage Criteria<sup>a</sup>:**

**A. Authorization**

**1. Seebri Neohaler** will be approved based on the following criterion:

a. History of failure, contraindication or intolerance to **both** of the following:

- 1) Spiriva Handihaler or Respimat (tiotropium)
- 2) Incruse Ellipta (umeclidinium)

**Authorization will be issued for 12 months.**

<sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

**3. Additional Clinical Rules:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may apply.

**4. References:**

1. Seebri Neohaler prescribing information. Sunovion Pharmaceuticals Inc: Marlborough, MA; January 2018.

Program	Step Therapy – COPD
<b>Change Control</b>	
Date	Change
6/2018	New program.
5/2019	Annual review. Added an authorization look back for current users and updated references.
6/2019	Tudorza Pressair was removed as a step 1 option